With all due respect, there is no point in doing comparisons...

First 605 Last

Share
Profile

Follow
Shellbell

7,740 Posts.

3286

16/02/24

13:36

Post #: 72444093
Share

Originally posted by Milcom: ↑

well, you are making the assumption. If they were diagnosed 5 months prior then patient D-F lived 11 months which is bang on average.

Fact is the share price is down from the 23rd October announcement. 11 patient trial is tiny. 5 of the patients showed no disease control. Only a couple showed longevity but who knows if that is due to factors other than the drug.

One patient surviving up to 18 months is nice but it does not point toward a wonder drug. I dont see anything that points toward SoC.

Only patient A and B showed good results but the data is far too small to matter at this stage. That still leaves 9 patients with no benefit over current survival rates.

Another study in 60 patients "The objective was to assess 2-year survival and quality of life in GBM patients who underwent primary surgery followed by chemo-radiotherapy and 6-month adjuvant chemotherapy with temozolomide."

"60 patients with GBM were analyzed, male to female ratio was 1.6:1. Patients most commonly presented with headache. Most common tumour site is the frontal lobe. The median overall survival (OS) was 10 months. The 1-year and 2-year survival rates were 30% and 6.7%, respectively."

Only 3% to 5% of patients survive more than three years, and reports of survival exceeding five years are sporadic

Expand

With all due respect, there is no point in doing comparisons between two different studies which in all likelihood have different parameters. You could well be comparing apples with oranges.

Phase 1 trials are typically small. And, if the trial you are referring to is this one: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826661/ ... then you are comparing apples with oranges.

Its a Ph 2 trial and the results pertain to a combination therapy! Twice the chance of the data being better than CHM-101.

Essentially, 101 is being trialed as a monotherapy... big difference, And, the recruitment target is for 42 patients.

This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).

Last edited by Shellbell: 16/02/24

CHM Price at posting: 2.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

1 Great analysis

Reply